FI20070808A0 - Splitsvarienter av GDNF och användningar därav - Google Patents

Splitsvarienter av GDNF och användningar därav

Info

Publication number
FI20070808A0
FI20070808A0 FI20070808A FI20070808A FI20070808A0 FI 20070808 A0 FI20070808 A0 FI 20070808A0 FI 20070808 A FI20070808 A FI 20070808A FI 20070808 A FI20070808 A FI 20070808A FI 20070808 A0 FI20070808 A0 FI 20070808A0
Authority
FI
Finland
Prior art keywords
gdnf
variants
split
split variants
Prior art date
Application number
FI20070808A
Other languages
English (en)
Finnish (fi)
Inventor
Tiina Lonka
Mart Saarma
Original Assignee
Mart Saarma
Tiina Lonka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mart Saarma, Tiina Lonka filed Critical Mart Saarma
Priority to FI20070808A priority Critical patent/FI20070808A0/sv
Publication of FI20070808A0 publication Critical patent/FI20070808A0/sv
Priority to US12/739,715 priority patent/US9579362B2/en
Priority to EP08842264A priority patent/EP2257570A4/en
Priority to AU2008316398A priority patent/AU2008316398A1/en
Priority to PCT/FI2008/050599 priority patent/WO2009053536A2/en
Priority to CN2008801228304A priority patent/CN102282165A/zh
Priority to JP2010530499A priority patent/JP2011500075A/ja
Priority to CA2703614A priority patent/CA2703614A1/en
Priority to EP12189585.8A priority patent/EP2551281B1/en
Priority to US15/424,505 priority patent/US10017553B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
FI20070808A 2007-10-25 2007-10-25 Splitsvarienter av GDNF och användningar därav FI20070808A0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FI20070808A FI20070808A0 (sv) 2007-10-25 2007-10-25 Splitsvarienter av GDNF och användningar därav
US12/739,715 US9579362B2 (en) 2007-10-25 2008-10-24 Splice variants of GDNF and uses thereof
EP08842264A EP2257570A4 (en) 2007-10-25 2008-10-24 SPONGE VARIANTS OF GDNF AND APPLICATIONS THEREOF
AU2008316398A AU2008316398A1 (en) 2007-10-25 2008-10-24 Splice variants of GDNF and uses thereof
PCT/FI2008/050599 WO2009053536A2 (en) 2007-10-25 2008-10-24 Splice variants of gdnf and uses thereof
CN2008801228304A CN102282165A (zh) 2007-10-25 2008-10-24 Gdnf剪接变体及其用途
JP2010530499A JP2011500075A (ja) 2007-10-25 2008-10-24 Ｇｄｎｆのスプライスバリアントおよびその用途
CA2703614A CA2703614A1 (en) 2007-10-25 2008-10-24 Splice variants of gdnf and uses thereof
EP12189585.8A EP2551281B1 (en) 2007-10-25 2008-10-24 Splice variants of GDNF and uses thereof
US15/424,505 US10017553B2 (en) 2007-10-25 2017-02-03 Splice variants of GDNF and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20070808A FI20070808A0 (sv) 2007-10-25 2007-10-25 Splitsvarienter av GDNF och användningar därav

Publications (1)

Publication Number Publication Date
FI20070808A0 true FI20070808A0 (sv) 2007-10-25

Family

ID=38656817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20070808A FI20070808A0 (sv) 2007-10-25 2007-10-25 Splitsvarienter av GDNF och användningar därav

Country Status (8)

Country Link
US (2) US9579362B2 (sv)
EP (2) EP2257570A4 (sv)
JP (1) JP2011500075A (sv)
CN (1) CN102282165A (sv)
AU (1) AU2008316398A1 (sv)
CA (1) CA2703614A1 (sv)
FI (1) FI20070808A0 (sv)
WO (1) WO2009053536A2 (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719582A1 (en) * 2008-03-25 2009-10-01 Amarantus Therapeutics, Inc. Methods and compositions for treating parkinson's disease with manf
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
RU2527169C2 (ru) * 2012-10-15 2014-08-27 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН) ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ, СОДЕРЖАЩАЯ hGDNF ПОД КОНТРОЛЕМ ТЕМПЕРАТУРОЧУВСТВИТЕЛЬНОГО ПРОМОТОРА ДЛЯ РЕГУЛИРУЕМОЙ ЭКСПРЕССИИ НЕЙРОТРОФИЧЕСКОГО ФАКТОРА КАК В КЛЕТКАХ, ТАК И НЕПОСРЕДСТВЕННО В ОРГАНИЗМЕ МЛЕКОПИТАЮЩИХ
CN103173489B (zh) * 2013-02-25 2015-09-09 潍坊易思特生物科技有限公司 用哺乳动物细胞生产高纯度糖基化的重组人胶质细胞源性神经营养因子的方法
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
CN103614481B (zh) * 2013-12-04 2015-12-30 徐州医学院 用于检测gdnf剪接变异体2、4的实时荧光定量pcr专用引物
TWI704156B (zh) * 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
BR112018073300A2 (pt) 2016-05-13 2019-03-26 Instituto De Medicina Molecular métodos para tratamento de doenças associadas com as células ilc3
AU2017351914B2 (en) * 2016-10-31 2020-09-10 Kolon Life Science, Inc. Composition for alleviating or treating pain
IL309027A (en) 2021-06-03 2024-02-01 Fundac?O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Neuro-messenger units that control ILC2 and obesity in brain fat cell circuit findings

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
DE19816186A1 (de) 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
ATE316576T1 (de) 1998-05-27 2006-02-15 Avigen Inc Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
CN1202129C (zh) * 2000-09-20 2005-05-18 中国人民解放军军事医学科学院基础医学研究所 Gdnf突变体及其治疗应用
AU2002359786A1 (en) 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
EP1660659A2 (en) 2003-09-05 2006-05-31 Licentia, Ltd. Gdnf-related neuropeptides
CA2627543A1 (en) 2005-10-28 2007-05-03 Ns Gene A/S Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf
EP1993590B1 (en) 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins

Also Published As

Publication number Publication date
EP2257570A2 (en) 2010-12-08
JP2011500075A (ja) 2011-01-06
WO2009053536A8 (en) 2011-09-15
WO2009053536A2 (en) 2009-04-30
EP2551281A1 (en) 2013-01-30
AU2008316398A1 (en) 2009-04-30
US10017553B2 (en) 2018-07-10
CA2703614A1 (en) 2009-04-30
US20170145066A1 (en) 2017-05-25
CN102282165A (zh) 2011-12-14
US20100311653A1 (en) 2010-12-09
EP2551281B1 (en) 2015-10-14
US9579362B2 (en) 2017-02-28
WO2009053536A3 (en) 2009-06-18
EP2257570A4 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
FI20070808A0 (sv) Splitsvarienter av GDNF och användningar därav
FI20075881A0 (sv) Medisinskt medel och tillverkning av detsamma
LTPA2015040I1 (lt) Vaistų farmakokinetinių savybių moduliatoriai
BRPI0906980A2 (pt) Composição de derivados e maleatados
DOP2010000044A (es) Derivado de oxopirazina y herbicida
BRPI0716147A2 (pt) modificaÇço dinÂmica de propriedades de vÍdeo
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
FI20065348A (sv) Spektrometer och interferometriskt förfarande
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
FI20105060A (sv) Bildstyrd ablation av plack
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2018158T3 (da) Ny racecadotril administrationsform
BRPI0809441A2 (pt) Formulação farmacêuticas de moléculas ghrh
FI20105938A0 (sv) Lysdiod och tillverkning av densamma
BRPI0719228A2 (pt) Composição estabilizada de prostaglandina e
DE602008005536D1 (de) Herstellung von MnB12H12
NO20083139L (no) Anvendelse av hyllebærekstrakt
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
BRPI0912074A2 (pt) composto e composição farmacêutica
DK2190451T3 (da) Behandling af atherosklerose
FI20085102A0 (sv) Ny användning av probioter
FR2896995B1 (fr) Raquette de paddleball
EP2168577A4 (en) MEDICAMENT HAVING THE EFFECT OF PROMOTING THE GROWTH OF HEPATOCYTES
FI20060590A0 (sv) Framställning av nanopartiklar
BRPI0915219A2 (pt) composições e métodos da laidlomicina

Legal Events

Date Code Title Description
FD Application lapsed